Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASN 100 (Primary)
  • Indications Pneumonia; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Arsanis

Most Recent Events

  • 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.
  • 09 Nov 2018 According to an Arsanis Biosciences media release, follow-up visits for all 154 patients who were enrolled in this study were completed and the trial database was locked during the third quarter of 2018.
  • 28 Jun 2018 Arsanis Biosciences has discontinued this trial following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC). The DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion and recommended that trial enrollment be discontinued. The company intends to conduct follow-up visits on all patients dosed with ASN100, according to an Arsanis Biosciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top